HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.

AuthorsRoberto de Franchis, Jaume Bosch, Guadalupe Garcia-Tsao, Thomas Reiberger, Cristina Ripoll
JournalJournal of hepatology (J Hepatol) Vol. 77 Issue 2 Pg. 567-568 (08 2022) ISSN: 1600-0641 [Electronic] Netherlands
PMID35526788 (Publication Type: Letter, Comment)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • atezolizumab
Topics
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Bevacizumab (adverse effects)
  • Carcinoma, Hepatocellular (etiology)
  • Humans
  • Hypertension, Portal (drug therapy, etiology)
  • Liver Neoplasms (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: